Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report

被引:35
作者
Oya, Yuko [1 ]
Yoshida, Tatsuya [1 ]
Uemura, Takehiro [1 ]
Murakami, Yoshiko [2 ]
Inaba, Yoshitaka [3 ]
Hida, Toyoaki [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Nagoya, Aichi 4648681, Japan
关键词
non-small cell lung cancer; small cell lung cancer transformation; anaplastic lymphoma kinase gene rearrangements; RESISTANCE; MUTATION; DNA;
D O I
10.3892/ol.2018.9158
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The resistance mechanisms to anaplastic lymphoma kinase (ALK) inhibitors comprise ALK gene variations, such as ALK point mutations and copy-number gains, the activation of bypass signaling through the activation of other oncogenes and small cell lung cancer (SCLC) transformation. To date, few studies have investigated whether tumor markers for SCLC correlate with the SCLC transformation in EGFR-mutant NSCLC and ALK-positive non-SCLC (NSCLC). The present case study reported a patient with SCLC transformation after alectinib treatment. The patient exhibited elevation of pro-gastrin-releasing peptide precursor and neuron-specific enolase levels, which may be predictive of SCLC transformation during the resistance to ALK-tyrosine kinase inhibitors.
引用
收藏
页码:4219 / 4222
页数:4
相关论文
共 12 条
[1]   Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment [J].
Bordi, Paola ;
Tiseo, Marcello ;
Rofi, Eleonora ;
Petrini, Iacopo ;
Restante, Giuliana ;
Danesi, Romano ;
Del Re, Marzia .
CLINICAL LUNG CANCER, 2017, 18 (06) :692-697
[2]   Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib [J].
Fujita, Shiro ;
Masago, Katsuhiro ;
Katakami, Nobuyuki ;
Yatabe, Yasushi .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) :E67-E72
[3]   Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [J].
Gainor, Justin F. ;
Dardaei, Leila ;
Yoda, Satoshi ;
Friboulet, Luc ;
Leshchiner, Ignaty ;
Katayama, Ryohei ;
Dagogo-Jack, Ibiayi ;
Gadgeel, Shirish ;
Schultz, Katherine ;
Singh, Manrose ;
Chin, Emily ;
Parks, Melissa ;
Lee, Dana ;
DiCecca, Richard H. ;
Lockerman, Elizabeth ;
Huynh, Tiffany ;
Logan, Jennifer ;
Ritterhouse, Lauren L. ;
Le, Long P. ;
Muniappan, Ashok ;
Digumarthy, Subba ;
Channick, Colleen ;
Keyes, Colleen ;
Getz, Gad ;
Dias-Santagata, Dora ;
Heist, Rebecca S. ;
Lennerz, Jochen ;
Sequist, Lecia V. ;
Benes, Cyril H. ;
Iafrate, A. John ;
Mino-Kenudson, Mari ;
Engelman, Jeffrey A. ;
Shaw, Alice T. .
CANCER DISCOVERY, 2016, 6 (10) :1118-1133
[4]   Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA [J].
Johnson, Alison C. ;
Do, Pascal ;
Richard, Nicolas ;
Dubos, Catherine ;
Michels, Jean Jacques ;
Bonneau, Jessica ;
Gervais, Radj .
LUNG CANCER, 2016, 99 :38-40
[5]   Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers [J].
Katayama, Ryohei ;
Shaw, Alice T. ;
Khan, Tahsin M. ;
Mino-Kenudson, Mari ;
Solomon, Benjamin J. ;
Halmos, Balazs ;
Jessop, Nicholas A. ;
Wain, John C. ;
Yeo, Alan Tien ;
Benes, Cyril ;
Drew, Lisa ;
Saeh, Jamal Carlos ;
Crosby, Katherine ;
Sequist, Lecia V. ;
Iafrate, A. John ;
Engelman, Jeffrey A. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)
[6]   Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK [J].
Katayama, Ryohei ;
Khan, Tahsin M. ;
Benes, Cyril ;
Lifshits, Eugene ;
Ebi, Hiromichi ;
Rivera, Victor M. ;
Shakespeare, William C. ;
Iafrate, A. John ;
Engelman, Jeffrey A. ;
Shaw, Alice T. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (18) :7535-7540
[7]   Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma [J].
Lodrini, Marco ;
Spruessel, Annika ;
Astrahantseff, Kathy ;
Tiburtius, Daniela ;
Konschak, Robert ;
Lode, Holger N. ;
Fischer, Matthias ;
Keilholz, Ulrich ;
Eggert, Angelika ;
Deubzer, Hedwig E. .
ONCOTARGET, 2017, 8 (49) :85234-85251
[8]   Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer [J].
Lovly, Christine M. ;
McDonald, Nerina T. ;
Chen, Heidi ;
Ortiz-Cuaran, Sandra ;
Heukamp, Lukas C. ;
Yan, Yingjun ;
Florin, Alexandra ;
Ozretic, Luka ;
Lim, Diana ;
Wang, Lu ;
Chen, Zhao ;
Chen, Xi ;
Lu, Pengcheng ;
Paik, Paul K. ;
Shen, Ronglai ;
Jin, Hailing ;
Buettner, Reinhard ;
Ansen, Sascha ;
Perner, Sven ;
Brockmann, Michael ;
Bos, Marc ;
Wolf, Juergen ;
Gardizi, Masyar ;
Wright, Gavin M. ;
Solomon, Benjamin ;
Russell, Prudence A. ;
Rogers, Toni-Maree ;
Suehara, Yoshiyuki ;
Red-Brewer, Monica ;
Tieu, Rudy ;
de Stanchina, Elisa ;
Wang, Qingguo ;
Zhao, Zhongming ;
Johnson, David H. ;
Horn, Leora ;
Wong, Kwok-Kin ;
Thomas, Roman K. ;
Ladanyi, Marc ;
Pao, William .
NATURE MEDICINE, 2014, 20 (09) :1027-1034
[9]   Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? [J].
Ou, Sai-Hong Ignatius ;
Lee, Thomas K. ;
Young, Lauren ;
Fernandez-Rocha, Maria Y. ;
Pavlick, Dean ;
Schrock, Alexa B. ;
Zhu, Viola W. ;
Milliken, Jeffrey ;
Ali, Siraj M. ;
Gitlitz, Barbara J. .
LUNG CANCER, 2017, 106 :110-114
[10]   Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients [J].
Paweletz, Cloud P. ;
Sacher, Adrian G. ;
Raymond, Chris K. ;
Alden, Ryan S. ;
O'Connell, Allison ;
Mach, Stacy L. ;
Kuang, Yanan ;
Gandhi, Leena ;
Kirschmeier, Paul ;
English, Jessie M. ;
Lim, Lee P. ;
Jaenne, Pasi A. ;
Oxnard, Geoffrey R. .
CLINICAL CANCER RESEARCH, 2016, 22 (04) :915-922